HUMA · Humacyte, Inc.

This delisting notice represents a material regulatory risk for Humacyte, as failure to regain compliance by November 2, 2026, could result in the removal of HUMA from The Nasdaq Global Select Market — a development that typically triggers reduced liquidity, diminished institutional investor participation, and potential collateral consequences for debt covenants or partnership agreements requiring Nasdaq listing. While Nasdaq’s 180-day grace period provides operational breathing room, the notice reflects sustained market pressure on the stock price, which may signal investor concerns about clinical progress, commercial execution, or capital structure. The filing explicitly states that the Company has no assurance it will regain compliance, and no concrete remediation plan — such as a reverse stock split — is disclosed. Although the notice does not impact current trading or SEC reporting, it elevates near-term governance and strategic focus toward share price stabilization, potentially diverting management attention from core R&D or commercial initiatives. Investors should closely monitor quarterly disclosures and any subsequent announcements regarding compliance efforts, as Nasdaq may require formal submission of a compliance plan or impose additional conditions during the review period.